• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 140

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Psilocybe Mushroom Pickers in Britain

Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026 Medical Psilocybin Launch; Radial Scores $50M; Otsuka’s “Novel Serotonergic Agonists”; Psilocybin Accelerates Brain...

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for...

The Fifteenth Horizons is Right Around the Corner

Numinus to Participate in a Water Tower Research Fireside Chat on...

Reunion Neuroscience Inc. Announces Executive Changes

PT362 – Cory Firth – Psychedelic Storytelling: Transforming Out Loud

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Silo Pharma to Present at the Dawson James Small Cap Growth...

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October...

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

1...139140141...304Page 140 of 304

EDITOR PICKS

Psilocybe Mushroom Pickers in Britain

Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026...

The Psychedelic News Feed: December 8 – 14, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©